1. Home
  2. OCSL vs GERN Comparison

OCSL vs GERN Comparison

Compare OCSL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oaktree Specialty Lending Corporation

OCSL

Oaktree Specialty Lending Corporation

HOLD

Current Price

$11.75

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.26

Market Cap

821.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCSL
GERN
Founded
2007
1990
Country
United States
United States
Employees
N/A
258
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
821.1M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
OCSL
GERN
Price
$11.75
$1.26
Analyst Decision
Hold
Hold
Analyst Count
4
3
Target Price
$12.63
$2.17
AVG Volume (30 Days)
750.9K
14.2M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
12.73%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
$0.31
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.63
$1.04
52 Week High
$14.77
$2.01

Technical Indicators

Market Signals
Indicator
OCSL
GERN
Relative Strength Index (RSI) 39.96 32.94
Support Level $10.88 $1.24
Resistance Level $13.19 $1.29
Average True Range (ATR) 0.28 0.09
MACD -0.08 -0.02
Stochastic Oscillator 11.89 10.42

Price Performance

Historical Comparison
OCSL
GERN

About OCSL Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: